Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Juan-Jose Lahuerta
Observed names:
J J Lahuerta,
J. Lahuerta,
J.J. Lahuerta,
Juan-José Lahuerta,
Juan‐José Lahuerta,
Lahuerta, J
show all 6
Institutions:
Research Institute Hospital 12 de Octubre,
Hospital Universitario 12 De Octubre,
Centro de Investigación Biomédica en Red de Cáncer
Observed institutions:
Research Institute Hospital 12 de Octubre,
Hospital Universitario 12 De Octubre,
Centro de Investigación Biomédica en Red de Cáncer
ORCID:
0000-0002-3393-9570
Observed ORCID:
0000-0002-3393-9570
OpenAlex ID:
A5152387303
Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
2006
·
Javier de la Rubia
, Joan Bladé
, et al.
·
PubMed
·
61
Favorable prognosis after late relapse of hodgkin's disease
1998
·
R. Garcia-Carbonero
, L. Paz-Ares
, et al.
·
Cancer
·
15
PDF
A critical analysis of the IMWG multiple myeloma complete response criterion in the era of mass spectrometry
2026
·
Noemí Puig
, Cristina Agulló
, et al.
·
HemaSphere
·
4
PDF
[Diabetes insipidus secondary to non-Hodgkin lymphoma].
1989
·
R Fernández-Rodríguez
, R Martínez
, et al.
·
PubMed
·
2
Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers
2026
·
Carmen Gonzalez
, Juan-Jose Garces
, et al.
·
Blood Cancer Discovery
·
1
[Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma].
1997
·
J García Laraña
, J Díaz Mediavilla
, et al.
·
PubMed
·
1
PA-044 Baseline Immune Fitness Defines a Transcriptional Subtype of Multiple Myeloma with Exceptional Response to Daratumumab-Based Regimens in the GEM2017FIT Trial
2026
·
Antonio Porlan Minarro
, Benat Ariceta Ganuza
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
LBA-08 MRD-Guided Frontline T-Cell Redirection Therapy for Newly Diagnosed High-Risk Multiple Myeloma Using Teclistamab-Daratumumab Intensification and Talquetamab-Daratumumab Early Rescue Intervention
2026
·
Paula Rodríguez-Otero
, Enrique M. Ocio
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
OA-63 Refining Frailty Assessment in Transplant-Ineligible Multiple Myeloma: Geriatric Assessment in Hematology Enhances the Simplified Frailty Index for Benefit-Risk Evaluation of Quadruplet Therapy
2026
·
Borja Puertas
, Anna Sureda
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-127 Daratumumab Plus Bortezomib Maintenance After DVMP Induction in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: 3-Year Real-World Outcomes Beyond the ALCYONE Strategy
2026
·
Luis-Esteban Tamariz-Amador
, Borja Puertas
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
OA-17 Discontinuation of Maintenance Therapy Guided by Minimal Residual Disease in Newly Diagnosed Multiple Myeloma: Long-Term Results of the GEM2014MAIN Study
2026
·
David F. Moreno
, Bruno Paiva
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
OA-12 Clinical Significance of Circulating Tumor Cells in Relapsed/Refractory Multiple Myeloma
2026
·
Daniel Bilek
, Esperanza Martín-Sanchez
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
B04 | Blood-based Risk Stratification of Myeloma Patients Using Circulating Tumor Cells: Results From the European Ctc Consortium
2026
·
L. Bertamini
, D. Zihala
, et al.
·
Haematologica
PDF
Effect of pamidronate on bone metabolism in patients with multiple myeloma in remission after autologous transplantation
2000
·
Diaz-Guerra, GM
, de la Serna, J
, et al.
·
Figshare
Show more works
View as search
Works count:
14
Citation count:
84
H-index:
3
I10-index:
2
Year
Topic
Type